New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo

NCT ID NCT04829383

Completed Disease control Sponsor: Howard S Hochster Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small, completed phase II study tested the safety of combining two drugs—atezolizumab (an immunotherapy) and bevacizumab (a blood vessel blocker)—in 6 people with advanced liver cancer who also had moderate cirrhosis (Child-Pugh B7 or B8). The goal was to see if this treatment could be safely given to patients who are often excluded from other trials. The study focused on tracking serious side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (Tecentriq) and bevacizumab (Avastin)
What this could lead to: If successful, this could show that the drug combination is safe enough to use in patients with more advanced liver disease, potentially expanding treatment options for this hard-to-treat group.
What could go wrong: This is a very small, early-phase feasibility study with only 6 participants, so results may not apply broadly. The drugs also carry risks of serious side effects, especially in patients with already-compromised liver function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNRESECTABLE HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

DHR Health Institute for Research and Development

Edinburg, Texas, 785329, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, 46202, United States
New York University Clinical Cancer Center

New York, New York, 10016, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Univeristy of Wisconsin

Madison, Wisconsin, 53705, United States
University of Illinois Cancer Center

Chicago, Illinois, 60612, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.